Amphomycin

Summary

Amphomycin is a calcium‑dependent cyclic lipopeptide antibiotic originally isolated from Streptomyces species. It is employed mainly as a topical antibacterial in veterinary practice and as a research tool to probe bacterial cell‑wall synthesis and lipid‑linked oligosaccharide pathways. The compound belongs to the amphomycin family of lipopeptides and is investigated for its ability to inhibit the essential membrane enzyme MraY, which catalyzes the first step of peptidoglycan assembly.

Mechanism of Action

Amphomycin binds to the lipid carrier undecaprenyl phosphate that serves as the substrate for the membrane‑bound translocase MraY (phospho‑MurNAc‑pentapeptide translocase). By forming a complex with this carrier, amphomycin blocks the transfer of phospho‑MurNAc‑pentapeptide onto undecaprenyl phosphate, halting the first membrane‑associated step of peptidoglycan precursor formation. In addition, studies on glycoprotein biosynthesis show that amphomycin interferes with the formation of dolichyl‑phosphoryl‑mannose, disrupting the lipid‑linked oligosaccharide pathway. Both actions impede essential cell‑wall or membrane‑associated processes in Gram‑positive bacteria.

What the Research Shows

Early investigations identified amphomycin as a member of the ten‑membered cyclic lipopeptide family that includes daptomycin and calcium‑dependent antibiotics. Although withdrawn from human therapeutic use, it remains marketed as a topical antibacterial for animals. Reviews of MraY inhibitors cite amphomycin as a natural example that inhibits the translocase by complexing the undecaprenyl phosphate co‑substrate, offering a scaffold for the design of broader‑spectrum agents. Structural and SAR studies of related lipopeptides have highlighted the potential for activity against resistant Gram‑positive strains, yet amphomycin itself has not progressed to clinical trials. Beyond antibacterial research, the compound has been employed as a biochemical probe to elucidate the topology of dolichyl‑phosphate in endoplasmic‑reticulum membranes, demonstrating utility in glycobiology. Overall, the literature supports amphomycin’s value as a tool compound rather than an approved drug.

Reported Benefits

Amphomycin provides a useful experimental probe for studying bacterial cell‑wall synthesis, specifically MraY inhibition, and for mapping dolichyl‑phosphate topology in eukaryotic membranes. Its inclusion in the lipopeptide family has informed structure‑activity analyses that guide the development of novel MraY inhibitors with activity against resistant Gram‑positive bacteria. In veterinary settings, topical formulations have been employed to control skin infections, although detailed efficacy data are limited.

Limitations of the Evidence

Amphomycin is no longer approved for human use and lacks clinical trial data, limiting conclusions about its therapeutic efficacy and safety. Reported activity is largely confined to in‑vitro or animal studies, and its antibacterial spectrum and potency have not been fully characterized. The compound’s toxicity profile remains unclear, and its complex cyclic lipopeptide structure poses challenges for large‑scale synthesis and formulation. Consequently, its current role is restricted to research and limited veterinary topical applications.

Safety Considerations

The safety profile of amphomycin in humans has not been established; its withdrawal from clinical use suggests potential concerns, although specific adverse effects are not detailed in the literature. In veterinary topical use, no systematic toxicity data are reported. When used experimentally, the compound is handled under standard laboratory safety precautions for bioactive peptides, and potential effects on host cell membranes or glycoprotein processing are considered. Caution is advised pending further toxicological evaluation.

How It Is Administered

Amphomycin is administered topically in veterinary products, typically as a cream or ointment applied to skin lesions. In research settings it can be delivered intravenously in solution for in‑vivo animal studies. The compound is supplied as a calcium‑complexed lipopeptide, requiring appropriate solubilisation for parenteral use.

Routes of Administration

Goals & Uses

• Gram-positive bacterial infection treatmentAntimicrobialLow
• treat resistant Gram‑positive infectionsAntibacterialModerate
• Topical antibacterial applicationAntimicrobialLow
• Inhibition of peptidoglycan biosynthesis (research tool)Research/mechanistic ProbeModerate

Contraindications

• Renal impairmentOrgan DysfunctionModerate
• Known hypersensitivity to amphomycin or related lipopeptidesAllergyHigh

Adverse Effects

• Hypersensitivity reactionsImmunologicUnknown
• Injection site reactionsLocalCommon
• NephrotoxicityRenalRare

Drug Interactions

• Nephrotoxic agents (e.g., aminoglycosides, NSAIDs)High

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant womenReproductiveRelative
• Patients with pre-existing renal diseaseOrgan DysfunctionRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization.
• United StatesUnapprovedInvestigational use only under IND.
• United KingdomUnapprovedNot licensed for clinical use.

No FDA, EMA, or MHRA approval; classified as an investigational new drug (IND) only for experimental use.

Evidence & Sources

• MraY Inhibitors as Novel Antibacterial Agents
  Journal ArticleModerateDini C2005-01-01T00:00:00.000000Z
• Natural products to drugs: daptomycin and related lipopeptide antibiotics
  Journal ArticleModerateBaltz RH, Miao V, Wrigley SK2005-01-01T00:00:00.000000Z
• A recent approach to the study of dolichyl monophosphate topology in the rough endoplasmic reticulum
  Journal ArticleModerateBanerjee DK1994-01-01T00:00:00.000000Z
• Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins
  Journal ArticleModerateBugg TD, Lloyd AJ, Roper DI2006-01-01T00:00:00.000000Z
• Inhibitors of the biosynthesis and processing of N-linked oligosaccharides
  Journal ArticleModerateElbein AD1984-01-01T00:00:00.000000Z
• The action mechanism of daptomycin
  Journal ArticleModerateTaylor SD, Palmer M2016-01-01T00:00:00.000000Z

Frequently Asked Questions